SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $10.5K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SABSW, Q2 2026
No superinvestor reported holding SABSW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by SAB Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2023 (view filing) | Dec 7 | 1 day | Sullivan Eddie JoeChief Executive Officer | PPurchase | +1.74K | $0.88 | +$1.53K | 0.0%5.23M after | |
| Nov 30, 2023 (view filing) | Nov 30 | Same day | King MichaelCHIEF FINANCIAL OFFICER | PPurchase | +5.00K | $0.90 | +$4.50K | New position5.00K after | |
| Nov 30, 2023 (view filing) | Nov 29 | 1 day | Reich Samuel JExecutive Chairman | PPurchase | +11.0K | $0.89 | +$9.79K | +5.3%219.0K after | |
| Sep 14, 2022 (view filing) | Sep 13 | 1 day | Hamilton Christine EDirector, 10% Owner | PPurchase | +10.0K | $0.73 | +$7.30K | +0.2%4.99M after | |
| Sep 8, 2022 (view filing) | Sep 7 | 1 day | Sullivan Eddie JoeCHIEF EXECUTIVE OFFICER | PPurchase | +14.0K | $0.74 | +$10.4K | +0.3%5.23M after | |
| Nov 16, 2021 (view filing) | Oct 26 | 21 daysLate | Beyer Russell PChief Financial Officer | SSale | −278 | $7.90 | −$2.20K | −100.0%0 after | |
| Oct 15, 2021 (view filing) | Oct 13 | 2 days | Katz IlanDirector, 10% Owner | PPurchase | +500 | $10.11 | +$5.05K | +50.0%1.50K after | |
| Oct 15, 2021 (view filing) | Oct 14 | 1 day | Reich Samuel JCEO and CFO | PPurchase | +1.00K | $10.11 | +$10.1K | New position1.00K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Spragens Jeffrey GDirector | PPurchase | +13.0K | $10.07 | +$130.9K | New position13.0K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Katz IlanDirector, 10% Owner | PPurchase | +1.00K | $10.09 | +$10.1K | New position1.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in SAB Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| LMR Partners LLP | 539,588 | $6.91K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 146,439 | $1.87K | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 79,033 | $1.01K | 0.00% | +300+0.4% | Added |
| GTS Securities LLC | 41,301 | $537 | 0.00% | +300+0.7% | Added |
| UBS Group AG | 6,567 | $85 | 0.00% | +2,381+56.9% | Added |
| Wolverine Asset Management LLC | 3,289 | $42 | 0.00% | +1,478+81.6% | Added |
| Toronto Dominion Bank | 300 | $4 | 0.00% | +300 | New |
| Virtu Financial LLC | 21,223 | $0 | 0.00% | +21,223 | New |